Antibodies
26 September 2016
Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA24 September 2016
Janssen Submits Application Seeking Approval of Sirukumab in United States for Rheumatoid Arthritis24 September 2016
FDA Approves Amgen’s AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases22 September 2016
Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform20 September 2016
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer20 September 2016
Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)19 September 2016
Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma19 September 2016
Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia19 September 2016
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia19 September 2016
Ultragenyx Reports New Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia19 September 2016
UCB receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoClicks® Prefilled Pen17 September 2016
CHMP Recommends Approval of Lilly’s Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma16 September 2016
Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine16 September 2016
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies15 September 2016
Last patient treated in Phase 1/2 trial with T-GuardTM in acute graft-versus-host disease15 September 2016
Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers14 September 2016
Elusys Therapeutics Announces Publication Of Results From Five Clinical Trials With Its Inhalational Anthrax Antitoxin, ANTHIM® (obiltoxaximab) Injection14 September 2016
MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCLNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports